Long-term Clinical Benefit of Mavacamten for Hypertrophic Cardiomyopathy in a Patient with RAF1 -associated Noonan Syndrome – Case Report
Clicks: 2
ID: 313376
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #218 of 261 articles by views in European Heart Journal - Case Reports
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 261 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and is frequently complicated by left ventricular outflow tract (LVOT) obstruction. While most cases are caused by sarcomeric mutations, up to 10% represent non-sarcomeric or syndromic phenocopies, including Noonan syndrome (NS). Noonan syndrome is a RASopathy in which mutations in genes such as RAF1 predispose to HCM through dysregulation of the Ras/MAPK pathway and are often associated with severe LVOT obstruction. Cardiac myosin inhibitors have demonstrated efficacy in sarcomeric obstructive HCM, but patients with syndromic HCM were excluded from pivotal clinical trials. Case summary We report a 29-year-old woman with long-standing obstructive HCM and NYHA class III symptoms, angina, and dizziness. Multimodality imaging demonstrated asymmetric septal hypertrophy (maximal wall thickness 20 mm), focal intramural late gadolinium enhancement, and dynamic LVOT obstruction reaching 55 mmHg during exercise. Owing to progressive obstruction, the patient was enrolled in the EXPLORER-HCM trial. During follow-up exceeding five years, treatment resulted in sustained reduction of LVOT gradients, improvement in functional status to NYHA class II, and complete resolution of angina and presyncope, without adverse effects. Genetic testing performed during trial participation identified a heterozygous likely pathogenic RAF1 variant, confirming Noonan syndrome-associated HCM. Discussion This case report demonstrates durable clinical and haemodynamic benefit of myosin inhibition in RAF1-associated Noonan syndrome HCM. This finding suggests that possible downstream hypercontractility may represent a shared and therapeutically targetable mechanism across sarcomeric HCM and selected syndromic phenocopies.
| Reference Key |
openalex_W7161393632
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Hanna Seghers, Bert Ectors, Maaike Alaerts, J S Saenen, Emeline M Van Craenenbroeck |
| Journal | European Heart Journal - Case Reports |
| Year | 2026 |
| DOI |
10.1093/ehjcr/ytag363
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.